Birk Venture

Accession Therapeutics, founded in 2020 and based in Oxford, United Kingdom, is focused on developing innovative immuno-oncology therapeutics aimed at treating challenging and widespread forms of cancer. The company's platform is designed to offer high specificity and potency, enabling it to effectively target various cancer cell variants while sparing healthy cells. Accession Therapeutics has pioneered a unique approach by engineering a viral point of entry into cancer cells, enhancing its ability to engage the immune system fully against tumors. This strategy aims to improve treatment outcomes for patients facing intractable cancer types.

Accession Therapeutics, founded in 2020 and based in Oxford, United Kingdom, is focused on developing innovative immuno-oncology therapeutics aimed at treating challenging and widespread forms of cancer. The company's platform is designed to offer high specificity and potency, enabling it to effectively target various cancer cell variants while sparing healthy cells. Accession Therapeutics has pioneered a unique approach by engineering a viral point of entry into cancer cells, enhancing its ability to engage the immune system fully against tumors. This strategy aims to improve treatment outcomes for patients facing intractable cancer types.

Zelluna Immunotherapy AS, founded in 2016 and based in Oslo, Norway, is a biopharmaceutical company dedicated to developing T-cell receptor (TCR) therapies for cancer treatment. The company aims to transform cancer therapy by creating TCR-based immunotherapies that can address various cancer types and patient needs. Zelluna's primary asset comprises a diverse portfolio of TCRs derived from patients who demonstrated long-term survival in peptide-based cancer vaccine trials conducted by Professor Gustav Gaudernack at the Norwegian Radium Hospital/Oslo University Hospital. Currently, several TCRs are in various stages of development. Zelluna is a member of the Oslo Cancer Cluster, an organization that fosters collaboration among stakeholders in cancer research and development, and is situated within the Oslo Cancer Cluster Innovation Park, adjacent to leading cancer treatment and research facilities.

APIM Therapeutics AS is a biotechnology company based in Trondheim, Norway, specializing in the development of combinatorial therapies for cancer treatment. Founded in 2009, the company focuses on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA), a crucial protein involved in DNA repair and cellular responses to stress. APIM Therapeutics is advancing its lead compound, ATX-101, which has demonstrated proof-of-concept in various preclinical in vitro and in vivo cancer models. The company's innovative approach aims to disrupt the interactions between PCNA and its binding partners, offering potential strategies to eliminate cancer-specific tumor cells.

Circio Holding ASA is a clinical-stage company dedicated to the development and commercialization of immuno-oncology therapies aimed at treating resistant solid tumors. Its primary product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to selectively infect cancer cells and stimulate the immune system to combat cancer more effectively. In addition to ONCOS-102, Circio's pipeline includes other candidates such as circVec and Mutant KRAS, which are focused on providing targeted immunotherapy solutions for cancer patients. The company's innovative approach seeks to enhance the efficacy of cancer treatments by leveraging the immune response, addressing a critical need in oncology for therapies that can overcome treatment resistance.

APIM Therapeutics AS is a biotechnology company based in Trondheim, Norway, specializing in the development of combinatorial therapies for cancer treatment. Founded in 2009, the company focuses on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA), a crucial protein involved in DNA repair and cellular responses to stress. APIM Therapeutics is advancing its lead compound, ATX-101, which has demonstrated proof-of-concept in various preclinical in vitro and in vivo cancer models. The company's innovative approach aims to disrupt the interactions between PCNA and its binding partners, offering potential strategies to eliminate cancer-specific tumor cells.

BerGenBio is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for aggressive cancers. Its leading drug candidate, bemcentinib, targets the receptor tyrosine kinase AXL and is currently undergoing clinical evaluation in a Phase 1b/2a study for first-line treatment of STK 11 mutated non-small cell lung cancer (NSCLC). Additionally, bemcentinib is in preclinical development for applications related to severe respiratory infections. The company's commitment lies in addressing significant unmet medical needs in oncology and beyond.

Nextera is a biotechnology company focused on developing novel therapeutic drugs aimed at disease-specific treatments. Its innovative platform leverages protein engineering and evolution technologies applicable in various fields, including life sciences, in vitro diagnostics, drug discovery, and lead optimization. The company specializes in high-resolution target discovery and lead candidate development, particularly in mechanisms associated with HLA class II. Nextera's therapeutics address major disease classes such as autoimmune diseases, chronic infections, and cancer, enhancing treatment efficacy while minimizing off-target side effects. Additionally, each lead developed by Nextera is accompanied by a companion diagnostic, ensuring a comprehensive approach to treatment and patient care.

Nordic Nanovector ASA is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with haematological cancers, particularly non-Hodgkin lymphoma (NHL). Its lead product candidate, Betalutin, is an antibody-radionuclide conjugate designed to target cancer cells effectively. Betalutin has shown promising results in a Phase I/IIa clinical trial, demonstrating both efficacy and tolerability in patients with difficult-to-treat NHL. The company is dedicated to addressing the significant unmet medical needs in this area and aims to retain marketing rights for Betalutin while exploring distribution agreements in select markets. In addition to Betalutin, Nordic Nanovector is committed to building a robust pipeline of novel antibody-radionuclide conjugates and antibody drug conjugates for various haematological malignancies, leveraging both proprietary technologies and collaborations with partner organizations. Founded in 2009 and headquartered in Oslo, Norway, Nordic Nanovector continues to advance its mission of improving patient outcomes in cancer therapy.